NTRA

Natera
D

NTRA

165.300
USD
0.83
(0.50%)
مغلق
حجم التداول
29,938
الربح لكل سهم
-2
العائد الربحي
-
P/E
-112
حجم السوق
22,571,149,674
أصول ذات صلة
G
GH
0.275
(0.56%)
49.295 USD
HOLX
HOLX
-0.450
(-0.69%)
64.750 USD
ILMN
ILMN
-1.120
(-1.27%)
87.000 USD
M
MYGN
-0.16000
(-3.08%)
5.04000 USD
PODD
PODD
0.89
(0.29%)
304.58 USD
Q
QGEN
-0.280
(-0.59%)
47.120 USD
TMO
TMO
-12.61
(-3.04%)
402.69 USD
VEEV
VEEV
0.37
(0.13%)
282.46 USD
المزيد
الأخبار المقالات

العنوان: Natera

القطاع: Healthcare
الصناعة: Diagnostics & Research
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.